Tibet AIM Pharm. Inc. (002826.SZ)

9.14 -0.28 (-2.97%) At close: 03:04PM CST

Tibet AIM Pharm. Inc.

Yingdu Building
Yingdu Building No. 48 Zhichun Road A Haidian District
Beijing
China
86 10 5873 1208
https://www.emyy.cn

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ke Xu	GM & Chairman	N/A	N/A	1978
Mr. Yu Zhang	Deputy GM & Non-Independent Director	N/A	N/A	1980
Ms. Qianjin Li	Deputy GM & Secretary of the Board of Directors	N/A	N/A	1977
Ms. Zhou Min	Financial Director & Director	N/A	N/A	1987

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; and NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain, as well as coma, spinal cord injury, cerebral infarction, hemorrhage, etc. It also provides Carbetocin injections for prevention of postpartum hemorrhage; Domperidone tablets for treatment of indigestion, abdominal bloating, belching, nausea, vomiting, and abdominal distension and pain; Montmorillonite powder for chronic diarrhea; Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotics, antiallergic, and digestive systems. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.

Corporate governance

Tibet AIM Pharm. Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.